BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
Phase 2
Completed
- Conditions
- Prostatic Hypertrophy, Benign
- Interventions
- Drug: Vardenafil (Levitra, BAY38-9456)Drug: Placebo
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT00461123
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate CancerNeoplasm Metastasis
- Interventions
- Drug: SalineDrug: Radium-223 dichloride (BAY88-8223)
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT00459654
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1420
- Registration Number
- NCT00459667
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 75
- Registration Number
- NCT00454558
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
Phase 3
Completed
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 460
- Registration Number
- NCT00453349
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 904
- Registration Number
- NCT00449033
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Phase 3
Completed
- Conditions
- Hot FlashesVasomotor Symptoms
- Interventions
- Drug: PlaceboDrug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)Drug: Estradiol (E2 0.3mg)
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 735
- Registration Number
- NCT00446199
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Phase 3
Completed
- Conditions
- Venous Thrombosis
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3449
- Registration Number
- NCT00440193
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Phase 3
Completed
- Conditions
- Pulmonary Embolism
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4833
- Registration Number
- NCT00439777
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Phase 3
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Rivaroxaban (Xarelto, BAY59-7939)Drug: Placebo
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1197
- Registration Number
- NCT00439725
© Copyright 2025. All Rights Reserved by MedPath